Skip to main content

Table 2 Character of included studies (treatment)

From: The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease

Study [first author, publish year] Country Study design Primordial therapy Sample size
(MSC/control)
Median age
(MSC/control)
Male (%)
(MSC/control)
Time of aGVHD diagnosis (mean days after HSCT) aGVHD grade MSC source MSC dose Number of MSC infusions Median duration of GVHD prior to enrollment Maximum follow-up (day)
Zhao K, 2015 [37] China nRCT HSCT 28/19 26/29 67.9%/63.2% 37/33 aGVHD: II-IV Bone marrow 1 × 106 cells/kg Once a week (until patients got CR or received 8 doses of MSCs) 17 (11–55) 1312
Szabolcs P, 2010 [39] Italy RCT HSCT 14/14 7/10 50.0%/71.4% NR aGVHD: II-IV Umbilical cord 2 × 106 cells/kg Once a week for 4 weeks (CR) or 8 weeks (PR) 20/8 139
Remberger, M, 2012 [38] Sweden nRCT HSCT 15/13 57/48 NR 63/56 aGVHD: III-IV NR 3 × 107 cells NR 8(0–37) 730
  1. NR not reported, CR complete response, PR partial response